splash-of-drugs
25 July 2013Americas

Ability to settle cases influences generic patent challenges, study finds

A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.

More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.

More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
24 April 2013   The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.